Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How can you possibly say that when 88% had no symptoms in three days and 100% at seven days and there were no reoccurrences 14 days out! F?
What is your problem?
Do you not remember that for 26 months, we were not trading? Because of the Weaponized government was protecting their Covid vaccine
Are you drunk or on drugs?
88% were symptom-free in three days! It was 100% effective.
Activity in Influenza and Respiratory Syncytial Virus highlights the broad- spectrum antiviral potential of ProLectin-M
BOSTON, MASSACHUSETTS, Feb. 28, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19, other viral diseases, and fibrosis announced today that in vitro testing at the Foundation for Neglected Disease Research (FNDR) in Bangalore India, showed that leading drug candidate ProLectin-M (PL-M) showed a significant reduction of viral load in influenza (H1N1) and in human Respiratory Syncytial Virus (RSV). The newest in vitro results, completed in early February 2023, are similar in nature to the SARS-CoV-2 test results that ultimately led to the successful completion of 2 clinical trials. The positive data and the non-toxic nature of the molecule justifies an IND filing to proceed to phase 2 human clinical trials.
These in vitro test results add to the body of evidence that PL-M has the potential to be a broad-spectrum antiviral useful in the treatment of Upper Respiratory Infections (“URI”) and as a potential treatment of populations infected by a “tripledemic” recently warned of by public health officials: that is peak infections, at the same time, of RSV, Influenza, and COVID-19. In December 2022 a wave of COVID-19, RSV, and Influenza infections hit all at once putting pressure on the hospital systems by maxing out the number of beds available. This pressure on the hospital systems had no relieve valve because there are no triage like treatments for standard risk patients.
Influenza has been infecting people worldwide since the 1500’s and the only way to control influenza is through the use of personal protective measures and frequent handwashing. There are a number of antiviral treatment options like oseltamivir phosphate (Tamiflu®) which was the positive control in our study, but these antivirals are designed to inhibit replication and must be taken within two days of symptoms. PL-M has a different mechanism of action as an entry inhibitor, and is designed to stop infectivity and spread of the disease throughout the body.
RSV is a highly contagious virus that primarily effects babies and older adults with underlying medical conditions and can lead to serious infections, including bronchiolitis, and pneumonia. There are over 57,000 hospitalizations, 500,000 emergency room visits and 1.5 million outpatient clinic visits among children less than 5 years of age that contract RSV. In adults there are 177,00 hospitalizations and 14,000 deaths annually.1 There are no known treatments except the management of the symptoms. Drug developers are working on vaccines and antiviral treatments.
With this excellent in vitro data in hand from influenza and RSV, the Company anticipates it will add additional treatment arms to its COVID-19 studies.
About ProLectin-M
ProLectin-M is an oral galectin antagonist that prevents the entry of the SARS-CoV-2 virus into human cells. In recent clinical trials the drug achieved a 100% responders rate of negative PCR tests by day 7. In 3 days, the drug achieved an 88% responders rate of negative PCR tests. The treated population experienced no viral rebounds during the 14-day observation period. The company is preparing for a phase 3 clinical trial in order to seek regulatory approval.
About Bioxytran, Inc.
Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidates, ProLectin-M (“PLM”) and ProLectin-I (“PLI”), are a new class of antiviral drugs designed to antagonize galectins implicated in viral, inflammatory, fibrotic, and malignant diseases. Bioxytran’s other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
1 CDC – National Notifiable Disease Surveillance System (NNDSS)
Primary Logo
Source: BIOXYTRAN, INC.
I think this is the longest message I’ve ever seen posted on the iHub
A promising new drug being trialed for Covid:
— Chris Turnbull (@EnemyInAState) March 26, 2023
'Most of the symptoms disappeared completely after receiving PL-M treatment for 7 days in more patients compared to the placebo group. Conclusion: PL-M is safe and effective for clinical..https://t.co/EmrUu0k03f
3 years ago they were focused on upgrading an existing building as the pilot plant!
That piefaced CEO said they were going to build a building from scratch. I got out! Stock plummeted!
So they have been building a facility in Fernley! How many $M have they spent?
Now 3 years later they are getting a move in ready facility!
I realized mr Pieface made his millions and left!
Any word on our legal case
Sorry. It did not open
After I posted it!
That is it!
Great news. Cytta Air : new division of the company
Cytta and FIZUAS Formulate Strategic Operating Partnership Expanding Upon Existing VAR Relationship
Cytta IGAN AIMS Technology Paired with FIZUAS Existing UAV Sales and Marketing Creates Powerful New Revenue Engine
Lubbock, Texas and Las Vegas, Nevada, March 17, 2023 – Cytta Corp (OTCQB: CYCA), announced that it is in final negotiations to determine the terms of the partnership between Cytta Corp and FIZUAS LLC (FIZUAS.com), a key provider of remote UAS communication, information, and IT solutions nationwide. The proposed name for the combined new entity is “Cytta Air.”
FIZUAS (Flight Information Zone Unmanned Aerial Systems) is a leading dealer in DJI, Autel, and Commaris drones and a trusted provider of remote UAS communication, information, and IT solutions nationwide. Cytta will be able to incorporate its IGAN technology as a value-added component to all existing and new sales, particularly the Commaris drones, under which Cytta has a valuable product development agreement.
Mr. Christopher Camelio, President, FIZUAS said, "Many of our customers are searching for new ways to increase their UAS utilization capability for surveillance, information gathering, and remote communications needs and better access to available video/audio capability. Our extensive experience with Cytta and our newly expanded partnership is a crucial step towards our collective objective of building the Nation's leading drone purveyor to Public Safety and a premier information collection and data utilization solutions provider." Mr. Camelio further stated " We will now jointly grow Cytta Air to fulfill customers' needs in today's drone, data and information focused world and significantly expand Cytta's revenue opportunities."
The proposed final Agreement will give Cytta Air the ability to expand communication solutions and professional services to Public Safety, First Responder, Energy, Agriculture, and Oil & Gas customers, driving new growth, sales, revenue, and market penetration of the nearly $50B market for drone sales and drone-based information, surveillance, and security communications marketplace.
"FIZUAS and their exceptionally talented team are a pioneering UA/UAV sales, operations, and service provider. They bring a wealth of experience, credibility, and strategic thinking that complements our technology and our team through our long working relationship. Collectively we feel we can build FIZUAS into the industry-leading drone and IGAN provision entity in America generating a significant revenue for Cytta," said Gary Campbell, CEO, Cytta Corp.
Cytta and FIZUAS have had an important strategic partnership since September 2019, with FIZUAS selling Cytta technology under a primary Value-Added Reseller (VAR) Agreement. The proposed new agreement would formalize the relationship between the two companies, creating a powerful managerial and operational partnership.
Please contact Cytta or our Sales team for a live demonstration of the IGAN AIMS technology for your department or organization. Mr. Bristol is available directly either by phone (612) 328- 6511 (please leave a message) or by email at JBristol@Cytta.com.
Gary Campbell, CEO of Cytta, discusses and highlights our 2023 business strategy during his recent interview on the CEO Roadshow. Learn more at www.cytta.com.
About Cytta Corp
Cytta Corp (OTCQB:CYCA): has created video/audio integration software with AI capability, advanced video compression, and portable/SaaS hardware/software systems that solve real- world problems in large markets. Cytta's IGAN AIMS (Actionable Information Management System) online dashboard integrates all video and audio streams, enabling collaborative interactivity while providing relevant, actionable information on an ongoing basis.
The IGAN Engine is a cloud based SAAS communication network providing a multifunctional tool for sharing realtime video, video/voice calls and chat interaction. The interactive desktop/mobile user interface provides quick visual reference and multiparty collaboration with streaming video, location maps, messages, and communications (video/voice/text). The IGAN Engine collaborative video, voice, chat and media integration tool makes it easy to share and store critical real time data, such as video feeds, images, chat, files, messages, location maps and media. IGAN’s complete encrypted cloud accessibility allows access as a web application for desktop and mobile devices, or with native iOS and Android mobile apps, all with end-to-end encryption for all users.
The IGAN AIMS is a practical, valuable, and irreplaceable tool for police, firefighters, first responders, emergency medical workers, industry, environmental and emergencies, security, military, and their command centers in a crisis. It also allows venues such as schools, malls, event venues, and religious locations to be connected and monitor their situation, as well as immediately make their data directly available to law enforcement during emergencies.
For more information, please visit cytta.com and the Corporate Cytta Video Channel on YouTube to view Cytta's recent corporate discussion videos. Learn more at www.cytta.com.
About FIZUAS
FIZUAS (Flight Information Zone-Unmanned Aircraft Systems) is a full life-cycle drone and small Unmanned Aircraft Systems (sUAS) company, utilizing AI, in the security, public safety, energy, oil and gas and agriculture industries. sUAS programs have many benefits, ranging from increased safety, decreased costs, and improved efficiency. FIZUAS team members offer expert systems design, consultation, preventative maintenance programs, training, and education. FIZUAS offers both in-person and online consultation service with industry leading experts. From Oil & Gas Pipelines and Pads, Police, Fire and Safety, Energy Grid Infrastructure, and
Agriculture, our industry solutions leverage the best technology, Artificial Intelligence (AI) and now best in class technology solutions delivering startling results to your business. Learn more at www.FIZUAS.com
Contact Us:
Cytta Corp
Phone: 855-511-IGAN (4265) http://www.cytta.com info@cytta.com
Natalia Sokolova, COO
Direct: (424) 333-0595 (or message) Natalia@cytta.com
John Bristol VP, Sales
Direct (612) 328-6511 (please leave a message) JBristol@Cytta.com
Stuart Brame, General Enquiries Direct 725 221 5757(or message) Stuart@cytta.com
It’s going to take time and money to get through clinical trials! More people see and hear of this, chances are it attracts some deep pocket investors!
file:///var/mobile/Library/SMS/Attachments/0c/12/4BF8C2C7-F1E4-487B-A6BE-E95E183CF188/FILE_1529.pdf
I think investors like ourselves should be posting this everywhere we can to get more eyes on this company increasing its exposure and presence to the general public!
Can you imagine the enormous importance it is to prove BIXT can cure a virus?
Maybe, with Mother’s Day being about two months away! They might do some business!
I think you’re using this board to promote ABT!
When was that news announcement and what was it going to be? Was there another smart product that was to be produced ? When is it launch date 2036? One every 13 years ?
This is exciting news! FistNet has a sales force. Just need to get them up to speed on the IGAN 2.0 !
The mm’s can control any OTC stock! Not surprising or unusual!
This is going to open doors for Cytta! This will have many people that really need this technology looking at it and talking about it! This will have a sales force of knowledgeable professionals discussing Cytta with the people that need it!
My opinion sales across the country will grow exponentially as people understand what it can do for them!
file:///var/mobile/Library/SMS/Attachments/45/05/91EB308C-4EE7-409D-A42D-0723334D736C/FILE_2255.pdf
Yes! I am very hopeful to the future of this company! I think we have a great team to move forward! And the spin off I think it’s going to be extremely effective in military sales!
For Cytta Corp
I believe sales will expand exponentially within various groups that employ our technology and by word of mouth create more demand for it!
State police
Sheriff department
County Boards
City police
Fire Department
Schools
Etc
This list is endless!
Randy1111, I don’t know who you are, but I have been involved with his company as a shareholder for years! Everything takes time to build and develop. and it takes time to generate momentum in sales.
I don’t know if we will have sales for this quarter ending in less than 30 days but I am 100% sure there will be sales in the next quarter!
Like all biotech companies, it takes lots of money to conduct clinical trials !
Was a good close on the week.
So very sad!
Bioxytran $BIXT:
Yesterday announced a significant drop in viral load of influenza and RSV! The world is standing at the threshold of a new era in medical history and they’re selling it at .36!
I guess in 1928 with the advent of penicillin there were some that didn’t believe it!
I bought more at $.362!
Bioxytran $Bixt
Activity in Influenza and Respiratory Syncytial Virus highlights the broad- spectrum antiviral potential of novel drug ProLectin-M. See full news !
So very sad!
Yes sir. I totally agree!
3! There are three 3 Ceo, bookkeeper & scientist in Israel if he still in !
The software engineers will work this out !
I do think that military sales will escalate as soon as we spin off RM !
This press release should be emailed to every personal contact you might have with any and all first responder group, police, fire, ambulance you personally know!
Let them see this.
Cytta Corp needs eyes on its products to demo what this advanced technology can do for them!
Yes! I think sales are going to sweep across this country in a exponential growth pattern!
This award from this homeland security is just the beginning to that happening !